Skip to main content

Advertisement

Table 3 Multivariate analysis of overall survival using the Cox regression in 1860 patients with NSCLC

From: Proportion and clinical features of never-smokers with non-small cell lung cancer

Variable Whole cohort (n = 1860) Never-smokers (n = 707) Ever-smokers (n = 1153)
HR 95% CI P HR 95% CI P HR 95% CI P
Smoking status     NA    NA   
 Ever-smoker 1.000         
 Never-smoker 0.624 0.460–0.848 0.003       
Agea 1.023 1.014–1.032 <0.001 1.005 0.988–1.021 0.582 1.029 1.018–1.040 <0.001
Sex          
 Male 1.000    1.000    1.000   
 Female 1.054 0.780–1.426 0.731 0.977 0.619–1.544 0.922 1.179 0.794–1.750 0.414
Histologic subtype          
 Adenocarcinoma 1.000    1.000    1.000   
 Squamous cell carcinoma 1.387 1.115–1.727 0.003 2.262 1.131–4.523 0.021 1.295 1.019–1.645 0.035
 Others 1.506 1.184–1.915 0.001 1.066 0.618–1.839 0.818 1.586 1.201–2.095 0.001
ECOG PS          
 0–1 1.000    1.000    1.000   
 2–4 2.098 1.725–2.552 <0.001 2.743 1.732–4.343 <0.001 1.976 1.589–2.457 <0.001
Symptoms at diagnosis          
 Asymptomatic 1.000    1.000    1.000   
 Symptomatic 0.722 0.610–0.854 <0.001 0.715 0.503–1.015 0.061 0.737 0.608–0.894 0.002
EGFR mutationsb          
 Absent 1.000    1.000    1.000   
 Present 0.493 0.381–0.637 <0.001 0.516 0.352–0.757 0.001 0.459 0.314–0.671 <0.001
KRAS mutationsb          
 Absent 1.000    1.000    1.000   
 Present 1.560 1.085–2.243 0.017 2.540 1.253–5.150 0.010 1.416 0.921–2.176 0.113
ALK rearrangementsb          
 Absent 1.000    1.000    1.000   
 Present 0.397 0.239–0.660 <0.001 0.225 0.105–0.484 <0.001 0.723 0.362–1.444 0.358
Stage          
 I 1.000    1.000    1.000   
 II 2.087 1.387–3.143 <0.001 3.995 1.365–11.694 0.011 1.810 1.163–2.818 0.009
 III 4.323 3.095–6.039 <0.001 4.470 1.872–10.671 0.001 4.036 2.797–5.824 <0.001
 IV 10.314 7.507–14.172 <0.001 23.067 10.840–49.085 <0.001 8.437 5.908–12.049 <0.001
Treatment          
 Supportive/unknown 1.000    1.000    1.000   
 Antitumor 0.634 0.516–0.780 <0.001 0.377 0.214–0.662 0.001 0.678 0.541–0.849 0.001
  1. NSCLC non-small cell lung cancer, HR hazard ratio, CI confidence interval, NA not applicable, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene homolog, ALK anaplastic lymphoma kinase
  2. aAge was used as a continuous variable
  3. bThe individuals who did not undergo testing for each mutation were included in the multivariate analysis, however, the data are not shown